BioSpace News Archive

Usona Institute activated its first clinical trial site within NYU School of Medicine, on October 15, 2019 for a Phase 2 clinical trial (PSIL201) investigating the safety and efficacy of psilocybin for major depressive disorder (MDD).

Xyphos Biosciences, Inc. and Gladstone Institutes today announced the publication of key preclinical data demonstrating that convertibleCAR® cells attack and significantly reduce latent reservoirs of diverse HIV strains

Tarveda Therapeutics®, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective precision oncology medicines for the treatment of patients with a wide range of solid tumor malignancies, today announced the publication of several preclinical studies evaluating PEN-221 as a novel therapeutic for the treatment of small cell lung cancer (SCLC).

Addressing the opioid crisis continues to be one of the FDA’s top public health priorities.

Flowonix Medical, Inc. today announced approval from the United States Food and Drug Administration (FDA) to market the Prometra II® 40 mL Programmable Pump and its associated programmer software.

New publication helps raise awareness of the impact of burnout on physicians and patients

Mauricio Silva, M.D., medical director at Los Angeles’ Orthopaedic Institute for Children, was one of a select group of trainers invited by the World Federation of Hemophilia to travel to Amman, Jordan, and participate at the Federation’s Regional Musculoskeletal Workshop for the Eastern Mediterranean Region.

Consortium Developed an Integrated Solution for Better Preparedness and Faster Response to Outbreaks and Epidemics in High-Risk Areas

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that Science magazine has named the company the world’s number one employer in its annual survey of the biotech and pharmaceutical industry.

Recent Medicare data demonstrates Northwestern as national leader in value-based healthcare